About ADmit Therapeutics
ADmit Therapeutics is a company based in Barcelona (Spain) founded in 2017 by Marta Barrachina and Jordi Gascon.. ADmit Therapeutics has raised $12.91 million across 5 funding rounds from investors including EIT Health, Ship2B and European Union. ADmit Therapeutics offers products and services including Early Detection Technology. ADmit Therapeutics operates in a competitive market with competitors including Todos Medical, Oxford Biodynamics, C₂N Diagnostics, Age Labs and Inherent Biosciences, among others.
- Headquarter Barcelona, Spain
- Founders Marta Barrachina, Jordi Gascon
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Admit Therapeutics, S.L.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$12.91 M (USD)
in 5 rounds
-
Latest Funding Round
$5.67 M (USD), Series A
Oct 05, 2023
-
Investors
EIT Health
& 11 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ADmit Therapeutics
ADmit Therapeutics offers a comprehensive portfolio of products and services, including Early Detection Technology. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Detects Alzheimer's disease early using specific biomarkers.
Unlock access to complete
Unlock access to complete
Funding Insights of ADmit Therapeutics
ADmit Therapeutics has successfully raised a total of $12.91M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $5.67 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 5
- Last Round Series A — $5.7M
- First Round First Round
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2023 | Amount | Series A - ADmit Therapeutics | Valuation | Alzheimer's Drug Discovery , European Union | |
| Jan, 2021 | Amount | Grant - ADmit Therapeutics | Valuation |
investors |
|
| Aug, 2020 | Amount | Series A - ADmit Therapeutics | Valuation | Ship2B |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ADmit Therapeutics
ADmit Therapeutics has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include EIT Health, Ship2B and European Union. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
WA4STEAM is focused on supporting women-led startups in STEAM fields.
|
Founded Year | Domain | Location | |
|
Clave is engaged in venture capital investments and management.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ADmit Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - ADmit Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Admit Therapeutics Comparisons
Competitors of ADmit Therapeutics
ADmit Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Todos Medical, Oxford Biodynamics, C₂N Diagnostics, Age Labs and Inherent Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Todos Medical is focused on developing diagnostic blood tests.
|
|
| domain | founded_year | HQ Location |
Personalized diagnostics are developed via epigenetics for biomarker detection.
|
|
| domain | founded_year | HQ Location |
Diagnostics and therapies for Alzheimer's disease are developed.
|
|
| domain | founded_year | HQ Location |
Molecular diagnostic solutions are developed for age-related disease detection.
|
|
| domain | founded_year | HQ Location |
Epigenetic diagnostics and therapeutics for complex diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Admit Therapeutics
Frequently Asked Questions about ADmit Therapeutics
When was ADmit Therapeutics founded?
ADmit Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is ADmit Therapeutics located?
ADmit Therapeutics is headquartered in Barcelona, Spain. It is registered at Barcelona, Catalonia, Spain.
Who is the current CEO of ADmit Therapeutics?
Marta Barrachina is the current CEO of ADmit Therapeutics. They have also founded this company.
Is ADmit Therapeutics a funded company?
ADmit Therapeutics is a funded company, having raised a total of $12.91M across 5 funding rounds to date. The company's 1st funding round was a Series A of $4.98M, raised on Aug 09, 2018.
What does ADmit Therapeutics do?
ADmit Therapeutics was founded in 2017 in Barcelona, Spain, within the biotechnology sector focused on neurodegenerative diagnostics. Services are centered on developing tests for early Alzheimers identification using next-generation sequencing to analyze biomarkers such as β-amyloid and tau. Epigenetic profiling of methylcytosines in mitochondrial DNA from blood samples is employed, supporting non-invasive detection methods for clinical applications.
Who are the top competitors of ADmit Therapeutics?
ADmit Therapeutics's top competitors include C₂N Diagnostics, Oxford Biodynamics and Age Labs.
What products or services does ADmit Therapeutics offer?
ADmit Therapeutics offers Early Detection Technology.
Who are ADmit Therapeutics's investors?
ADmit Therapeutics has 12 investors. Key investors include EIT Health, Ship2B, European Union, European Investment Fund, and Lavanda.